Regulatory
Reston Hospital Center has received the American Heart Association/American Stroke Association’s Get With The Guidelines® Target: Stroke Honor Roll Elite Gold Plus Quality Achievement Award.
Biofrontera AG, an international biopharmaceutical company, reports preliminary unaudited revenue for the first six months of fiscal year 2019.
Cellectar Biosciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation for CLR 131 in relapsed or refractory Diffuse Large B-Cell Lymphoma.
CorMedix Inc. announced that it has received feedback from the U.S. FDA regarding the submitted statistical analyses of data and additional information requested by the FDA for the primary and secondary efficacy endpoints of the Company’s LOCK-IT-100 clinical study.
Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio
SonoCloud ultrasound device for glioblastoma patients will be tested for first time at US clinical sites
The judge ruled that the U.S. Department of Health and Human Services did not have the authority to compel companies to disclose the list prices without Congressional approval.
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Da Volterra, a clinical-stage biopharmaceutical company developing new therapeutics to protect the intestinal microbiota, announced the completion of patient recruitment for its Phase 2 trial ‘SHIELD’ evaluating DAV132 in patients receiving antibiotics.
PRESS RELEASES